Study on Revumenib with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutation

Inclusion Criteria

• Must have been newly diagnosed with AML and not yet treated, and be eligible for intensive chemotherapy.
• Must have a specific genetic mutation known as NPM1.
• Must have a performance status score of 2 or less, or 1 or less if over 65 years old, indicating good overall health.
• Must have a life expectancy of at least 3 months, as determined by the study doctor.
• Must have a negative pregnancy test if applicable.
• Must have adequate liver, kidney, and heart function.

Exclusion Criteria

• Cannot have a diagnosis of active acute promyelocytic leukemia.
• Cannot have active disease affecting the central nervous system.
• Cannot have a heart condition that affects the QT interval on an ECG, or a family history of Long QT syndrome.
• Cannot have gastrointestinal issues that affect the ability to take oral medication.
• Cannot have another active cancer that requires treatment, except for stable breast or prostate cancer on hormone therapy.
• Cannot be unable to swallow pills.
• Cannot be pregnant or breastfeeding.
• Cannot have active or chronic hepatitis B, active hepatitis C, or HIV with a detectable viral load.